We are live on ! Find out more
PNT

POINT Biopharma Global Inc. Common Stock
PNT

Delisted

PNT was delisted on the 26th of December, 2023.

Back to rankings

106 hedge funds and large institutions have $470M invested in POINT Biopharma Global Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 40 increasing their positions, 21 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

220% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 10

90% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 21

42% more capital invested

Capital invested by funds: $330M → $470M (+$140M)

26% more funds holding

Funds holding: 84 → 106 (+22)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
106
Holders Change
+22
Holders Change %
+26.19%
% of All Funds
1.83%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
32
Increased
40
Reduced
21
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PHS
PFM Health Sciences
California
+$38.3M
2
APM
Avidity Partners Management
Texas
+$23.9M
3
BI
BVF Inc
California
+$18.9M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$14.8M
5
Citadel Advisors
Citadel Advisors
Florida
+$11.6M

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$61.3M
2
SCM
Suvretta Capital Management
New York
-$5.8M
3
PA
Perceptive Advisors
New York
-$4.87M
4
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$3.95M
5
RI
RTW Investments
New York
-$3.34M
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
76
Morgan Stanley
New York
$155K -$482K -56,754 -74%
Teacher Retirement System of Texas
77
Teacher Retirement System of Texas
Texas
$141K +$155K +18,227 New
SO
78
STRS Ohio
Ohio
$132K – – –
OQS
79
Occudo Quantitative Strategies
Florida
$128K +$141K +16,615 New
VEA
80
Virtus ETF Advisers
New York
$117K +$900 +106 +0.7%
BCM
81
Bayesian Capital Management
New York
$116K +$127K +14,962 New
CA
82
Claro Advisors
Massachusetts
$108K – – –
Ensign Peak Advisors
83
Ensign Peak Advisors
Utah
$105K +$8.66K +1,020 +8%
State Board of Administration of Florida Retirement System
84
State Board of Administration of Florida Retirement System
Florida
$101K – – –
SSA
85
Schonfeld Strategic Advisors
New York
$96K +$105K +12,400 New
CIBC World Market
86
CIBC World Market
Ontario, Canada
$95K – – –
AB
87
Amalgamated Bank
New York
$91K +$1.49K +176 +2%
American Century Companies
88
American Century Companies
Missouri
$90K +$98.9K +11,651 New
ASRS
89
Arizona State Retirement System
Arizona
$85K +$263 +31 +0.3%
TRCT
90
Tower Research Capital (TRC)
New York
$84K -$5.6K -660 -6%
Principal Financial Group
91
Principal Financial Group
Iowa
$82K -$3.79K -446 -4%
EFM
92
E Fund Management
China
$79K +$86.7K +10,212 New
Tudor Investment Corp
93
Tudor Investment Corp
Connecticut
$79K +$87.3K +10,282 New
Wells Fargo
94
Wells Fargo
California
$70K -$3.68K -434 -5%
LSA
95
Leonteq Securities AG
Switzerland
$69.6K – – –
Zurich Cantonal Bank
96
Zurich Cantonal Bank
Switzerland
$66K +$72K +8,481 New
AIP
97
Ameritas Investment Partners
Nebraska
$42K – – –
MLICM
98
Metropolitan Life Insurance Company (MetLife)
New York
$36.7K – – –
PVH
99
Psagot Value Holdings
Israel
$31K +$34K +4,000 New
Osaic Holdings
100
Osaic Holdings
Arizona
$21K – – –
1 2 3
4
5

PNT Hedge Fund Activity: Q3 2022 in Review

106 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in POINT Biopharma Global Inc. Common Stock (PNT) for Q3 2022, worth a combined $470M — up 42% from $330M a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new PNT positions and 10 closed out — a net gain of 22 holders — while 40 added to existing stakes and 21 trimmed.

The largest buyer was PFM Health Sciences, opening a new position worth an estimated $38.3M. The largest seller was RA Capital Management, exiting entirely with an estimated $61.3M sold.

  • 106 institutional investors held POINT Biopharma Global Inc. Common Stock (PNT) as of Q3 2022, up from 84 in Q2 2022.
  • Funds reported $470M of POINT Biopharma Global Inc. Common Stock stock for Q3 2022, up 42% quarter-over-quarter.
  • 32 funds opened new POINT Biopharma Global Inc. Common Stock positions in Q3 2022 and 10 closed out, a net change of +22 holders.
  • The largest POINT Biopharma Global Inc. Common Stock buyer in Q3 2022 was PFM Health Sciences, an estimated $38.3M added.
  • The largest POINT Biopharma Global Inc. Common Stock seller in Q3 2022 was RA Capital Management, an estimated $61.3M sold.

Based on aggregated 13F filings for Q3 2022.